


## Abstract

Phenylalanine enamide derivatives of formula (1) are described:



5

wherein  $R^1$  is a  $-\text{CH}_3$ ,  $-(\text{CH}_2)_3\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{CH}_2\text{OCH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3$ ,

$-\text{CH}_2\text{CH}_2-\text{N} \begin{array}{c} \diagup \quad \diagdown \\ \text{O} \end{array} \quad \text{or} \quad -\text{CH}_2\text{CH}_2-\text{N} \begin{array}{c} \diagup \quad \diagdown \\ \text{N}-\text{CH}_3 \end{array}$

10 group;

and the salts, solvates and N-oxides thereof.

Compounds according to the invention are potent and selective inhibitors of  $\alpha_4$  integrins. The compounds are of use in modulating cell adhesion and in particular are of use in the prophylaxis and treatment of diseases or disorders including inflammation in which the extravasation of leukocytes plays a role and the invention extends to such a use and to the use of the compounds for the manufacture of a medicament for treating such diseases or disorders.

20